Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors: Preliminary study on a small group of recruits

Fabiola Cecchi, Stefania Pacini, Massimo Gulisano, Claudio MacChi, Claudio Catini, Raffaello Molino Lova, Gianni Fuzzi, Marco Ruggiero, Simonetta Vannucchi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Glycosaminoglycans in normal human plasma, mainly represented by chondroitin sulfates and heparan sulfates/heparin (HSGAGs), show a specific distribution in the Cohng-Oncley fractions of human plasma. In the present study we investigated their effects on coagulation. Plasma was fractionated following the procedure of Cohng-Oncley, and each fraction was treated for extraction of glycosaminoglycans after extensive proteolysis; the anticoagulant activity in the extracted samples was measured by activated partial thromboplastin time (APTT). The effects of the samples containing HSGAGs on factor II and factor X activities, before and after treatment with heparinase I, were also measured. The molecular weight of HSGAGs was determined by polyacrylamide gel-electrophoresis. Cryoprecipitate and fraction I, fraction II+III, and fraction IV-1 (the fractions containing HSGAGs) prolonged the APTT, whereas fractions IV-4 and V had no effect on the APTT. Fractions containing HSGAGs showed effects on factor II and factor X activities that were sensitive to heparinase I treatment. The molecular weight of HSGAGs recovered in cryoprecipitate and fraction I was 15g-18 kDa; that of HSGAGs recovered in fraction IV-1 was 12.0 kDa. In conclusion, these results demonstrate that HSGAGs of different molecular weight, endowed with anticoagulant activity, circulate in normal human plasma in association with specific proteins involved in the regulation of hemostasis; and that endogenous HSGAGs play a role in maintaining the antithrombotic/hemostatic balance in normal human plasma.

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalBlood Coagulation and Fibrinolysis
Volume19
Issue number5
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Heparitin Sulfate
Glycosaminoglycans
Anticoagulants
Heparin
Partial Thromboplastin Time
Heparin Lyase
Factor X
Molecular Weight
Prothrombin
Chondroitin Sulfates
Hemostatics
Hemostasis
Proteolysis
Polyacrylamide Gel Electrophoresis
Proteins

Keywords

  • Anticoagulant activity
  • Glycosaminoglycans
  • Human plasma

ASJC Scopus subject areas

  • Hematology

Cite this

Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors : Preliminary study on a small group of recruits. / Cecchi, Fabiola; Pacini, Stefania; Gulisano, Massimo; MacChi, Claudio; Catini, Claudio; Lova, Raffaello Molino; Fuzzi, Gianni; Ruggiero, Marco; Vannucchi, Simonetta.

In: Blood Coagulation and Fibrinolysis, Vol. 19, No. 5, 07.2008, p. 349-354.

Research output: Contribution to journalArticle

Cecchi, Fabiola ; Pacini, Stefania ; Gulisano, Massimo ; MacChi, Claudio ; Catini, Claudio ; Lova, Raffaello Molino ; Fuzzi, Gianni ; Ruggiero, Marco ; Vannucchi, Simonetta. / Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors : Preliminary study on a small group of recruits. In: Blood Coagulation and Fibrinolysis. 2008 ; Vol. 19, No. 5. pp. 349-354.
@article{1a1cfa481fc54766a8284c269444f813,
title = "Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors: Preliminary study on a small group of recruits",
abstract = "Glycosaminoglycans in normal human plasma, mainly represented by chondroitin sulfates and heparan sulfates/heparin (HSGAGs), show a specific distribution in the Cohng-Oncley fractions of human plasma. In the present study we investigated their effects on coagulation. Plasma was fractionated following the procedure of Cohng-Oncley, and each fraction was treated for extraction of glycosaminoglycans after extensive proteolysis; the anticoagulant activity in the extracted samples was measured by activated partial thromboplastin time (APTT). The effects of the samples containing HSGAGs on factor II and factor X activities, before and after treatment with heparinase I, were also measured. The molecular weight of HSGAGs was determined by polyacrylamide gel-electrophoresis. Cryoprecipitate and fraction I, fraction II+III, and fraction IV-1 (the fractions containing HSGAGs) prolonged the APTT, whereas fractions IV-4 and V had no effect on the APTT. Fractions containing HSGAGs showed effects on factor II and factor X activities that were sensitive to heparinase I treatment. The molecular weight of HSGAGs recovered in cryoprecipitate and fraction I was 15g-18 kDa; that of HSGAGs recovered in fraction IV-1 was 12.0 kDa. In conclusion, these results demonstrate that HSGAGs of different molecular weight, endowed with anticoagulant activity, circulate in normal human plasma in association with specific proteins involved in the regulation of hemostasis; and that endogenous HSGAGs play a role in maintaining the antithrombotic/hemostatic balance in normal human plasma.",
keywords = "Anticoagulant activity, Glycosaminoglycans, Human plasma",
author = "Fabiola Cecchi and Stefania Pacini and Massimo Gulisano and Claudio MacChi and Claudio Catini and Lova, {Raffaello Molino} and Gianni Fuzzi and Marco Ruggiero and Simonetta Vannucchi",
year = "2008",
month = "7",
doi = "10.1097/MBC.0b013e3282ef9a0e",
language = "English",
volume = "19",
pages = "349--354",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors

T2 - Preliminary study on a small group of recruits

AU - Cecchi, Fabiola

AU - Pacini, Stefania

AU - Gulisano, Massimo

AU - MacChi, Claudio

AU - Catini, Claudio

AU - Lova, Raffaello Molino

AU - Fuzzi, Gianni

AU - Ruggiero, Marco

AU - Vannucchi, Simonetta

PY - 2008/7

Y1 - 2008/7

N2 - Glycosaminoglycans in normal human plasma, mainly represented by chondroitin sulfates and heparan sulfates/heparin (HSGAGs), show a specific distribution in the Cohng-Oncley fractions of human plasma. In the present study we investigated their effects on coagulation. Plasma was fractionated following the procedure of Cohng-Oncley, and each fraction was treated for extraction of glycosaminoglycans after extensive proteolysis; the anticoagulant activity in the extracted samples was measured by activated partial thromboplastin time (APTT). The effects of the samples containing HSGAGs on factor II and factor X activities, before and after treatment with heparinase I, were also measured. The molecular weight of HSGAGs was determined by polyacrylamide gel-electrophoresis. Cryoprecipitate and fraction I, fraction II+III, and fraction IV-1 (the fractions containing HSGAGs) prolonged the APTT, whereas fractions IV-4 and V had no effect on the APTT. Fractions containing HSGAGs showed effects on factor II and factor X activities that were sensitive to heparinase I treatment. The molecular weight of HSGAGs recovered in cryoprecipitate and fraction I was 15g-18 kDa; that of HSGAGs recovered in fraction IV-1 was 12.0 kDa. In conclusion, these results demonstrate that HSGAGs of different molecular weight, endowed with anticoagulant activity, circulate in normal human plasma in association with specific proteins involved in the regulation of hemostasis; and that endogenous HSGAGs play a role in maintaining the antithrombotic/hemostatic balance in normal human plasma.

AB - Glycosaminoglycans in normal human plasma, mainly represented by chondroitin sulfates and heparan sulfates/heparin (HSGAGs), show a specific distribution in the Cohng-Oncley fractions of human plasma. In the present study we investigated their effects on coagulation. Plasma was fractionated following the procedure of Cohng-Oncley, and each fraction was treated for extraction of glycosaminoglycans after extensive proteolysis; the anticoagulant activity in the extracted samples was measured by activated partial thromboplastin time (APTT). The effects of the samples containing HSGAGs on factor II and factor X activities, before and after treatment with heparinase I, were also measured. The molecular weight of HSGAGs was determined by polyacrylamide gel-electrophoresis. Cryoprecipitate and fraction I, fraction II+III, and fraction IV-1 (the fractions containing HSGAGs) prolonged the APTT, whereas fractions IV-4 and V had no effect on the APTT. Fractions containing HSGAGs showed effects on factor II and factor X activities that were sensitive to heparinase I treatment. The molecular weight of HSGAGs recovered in cryoprecipitate and fraction I was 15g-18 kDa; that of HSGAGs recovered in fraction IV-1 was 12.0 kDa. In conclusion, these results demonstrate that HSGAGs of different molecular weight, endowed with anticoagulant activity, circulate in normal human plasma in association with specific proteins involved in the regulation of hemostasis; and that endogenous HSGAGs play a role in maintaining the antithrombotic/hemostatic balance in normal human plasma.

KW - Anticoagulant activity

KW - Glycosaminoglycans

KW - Human plasma

UR - http://www.scopus.com/inward/record.url?scp=67649513477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649513477&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e3282ef9a0e

DO - 10.1097/MBC.0b013e3282ef9a0e

M3 - Article

C2 - 18600081

AN - SCOPUS:67649513477

VL - 19

SP - 349

EP - 354

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 5

ER -